<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750425</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00020</org_study_id>
    <secondary_id>EUDRACT number 2008-002271-27</secondary_id>
    <nct_id>NCT00750425</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours</brief_title>
  <official_title>A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÃ”), in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the
      body handles the experimental drug cediranib, in patients with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the steady-state PK parameters of cediranib in the presence and absence of ketoconazole.</measure>
    <time_frame>PK assessments to be taken until Day 42. Days 7 and 10 PK parameters used to assess the primary variables.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of cediranib in the presence of ketoconazole by assessment of Adverse events (AEs) Laboratory findings,Vital signs, physical examination and Electrocardiogram.</measure>
    <time_frame>Until study drug is discountinued</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib (RECENTIN TM, AZD2171)</intervention_name>
    <description>20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histological or cytological confirmation of advanced solid tumour (with the exception
             of prostate cancer), which is refractory to standard therapies or for which no
             standard therapy exists.

          -  Estimated life expectancy of at least 8 weeks

          -  WHO performance status (PS) 0-2.

        Exclusion Criteria:

          -  Unstable brain/meningeal metastases

          -  Biochemistry/haematology results outside of required ranges

          -  History of significant GI impairment

          -  Inadequate bone marrow reserve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Roberston</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Aderley Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr U Lassen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Finsen Center, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobenhavn</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jane Robertson, Medical Science Director, RECENTIN</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>advanced cancer,</keyword>
  <keyword>metastatic</keyword>
  <keyword>ketoconazole</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Phase I</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

